

References

Abdi W, Milla JC, Mezey E.(1979) Sampling variability on percutaneous liver biopsy. Arch,Intern.Med.;139:667-669.

Alter MJ, Kruszon-Moran D, Nainon OV, et al.(1999) The prevalence of hepatitis C virus infection in United States, 1998 through 1994. N Engl J Med 1999;341:556–62.

Amin J, Gidding H, Gilbert G, Backhouse J, Kaldor J, Dore G, Burgess M.(2004) Hepatitis C prevalence – a nationwide serosurvey. Commun Dis Intell. 2004; 28(4):517-21.

Agnello V, De Rosa FG (2004). Extrahepatic disease manifestations of HCV infection: some current issues. J. Hepatol.; 40: 341- 352.

Antonelli A, Ferri C, Pampana A, et al (2004). Thyroid disorders in chronic hepatitis C. Am. J. Med.; 117: 10-13.

Reference

Arthur K, Russell T, John R, Daniel H, Solomon MP, Henry A, Homburger MD (2000). Guidelines for Clinical Use of the Antinuclear Antibody Test and Tests for Specific Autoantibodies to Nuclear Antigens. Arch Pathol Lab Med.; Vol. 124.

Assy N, Minuk GY(2000). Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am. J. Gastroenterol. ;95:1545–50.

Blubak ME, Porayko MK, Krom RAF et al.(1991) Complication of liver biopsy in liver transplant patients: increase sepsis associated with choledochojejunostomy. Hepatology; 14:1603-1605.

Boyer N, Marcellin P (2000). Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 32:98-112.

Buscarini L, Fornari F, Bolondi L, et al.(1990) Ultrasound-guided fine-needle biopsy of focal liver lesions: techniques, diagnostic accuracy and complications. J.Hepatol.; 11:344.

Reference

Cacoub P, Renou C, Rosenthal E. et al (2000). Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multi center study of 321 patients. *Medicine (Baltimore)*; 79: 47–56.

Caronia S, Taylor K, Pagliaro L, et al (1999). Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. *Hepatology*; 30: 1059-1063.

Cassani F, Cataleta M, Valentini P, et al(1997). Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. *Hepatology*;26:561–6.

Caturelli E, Giacobbe A, Facciorusio D, et al.(1996) Percutaneous biopsy in diffuse liver disease: increasing diagnostic yield and decreasing complication rate by routine ultrasound assessment of puncture site. *Am J Gastroenterol*; 91:1318-1321.

Chretien P, Chousterman M, Abd Alsamad I, Ozenne V, Et al(2009). Non-organ-specific autoantibodies in chronic hepatitis C patients : Association with histological activity and fibrosis. *Journal of Autoimmunity*, 32: 201-205.

Reference

Chrisoffersen P, Poulsen H, Skeie E.(1970) Focal liver necrosis accompanied by infiltration of granulocytes arising during operation. Acta Hepato-Splenologica; 17:240-245.

Clarke B.(1999) Molecular virology of hepatitis C virus J Gen Virol 78:2397-2410, 1997.

Clifford BD. Donahue D, Smith L, et al(1995). High prevalence of serological markers of Autoimmunity in patients with chronic hepatitis C. Hepatology 17:75-9.

Colin c, et al (2001). Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J. Viral Hepat.;8:87-95.

College of American Pathologists (1997).Commission of Laboratory Accreditation Inspection Checklist : Diagnostic Immunology and Syphilis Serology. Northbrook, III: College of American Pathologists.

Dalekos GN, Makri E, Loges S, Obermayer-Straub P, Zachou K, Tsikrikas T, Schmidt E, Papadamou G, Manns MP (2002). Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. Eur. J. Gastroenterol. Hepatol .; 14:35-42.

Reference

- DeCastro M, Sanchez J, Herrera JF, et al (1993).** Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. *Hepatology*; 17: 551-557.
- Deuffic-Burban S, Mohamed MK, Larouze B, Carrat F, Valleron AJ.(2006).** Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. *J Hepatol.*;44(3):455-61.
- Dienstag JL(2002)** The role of live biopsy in chronic hepatitis C. *Hepatology*;36: S152-S160.
- Dixon AK, Nunez DJ, Bradley JR, et al.(1987)** Failure of percutaneous liver biopsy: anatomical variation. *Lancet*; 2:437-439.
- Donahue JG, Munoz A, Ness PM,Brown DE Jr, Yawn DH, McAllister HA Jr, Reitz BA, Nelson KE.(1992)** The declining risk of post-transfusion hepatitis C virus infection. *N Engl J Med.*;327(6):369-73.
- Dotter CT(2004)** Catheter biopsy. Experimental technique for transvenous liver biopsy. *Radiology*;82:312-314.
- Fang SH, Hwang LH, Chen DS, Chiang BL(2000).** Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. *J. Hepatol.*; 33:791-798.

Reference

- Forslid J, Heigl Z, Jonsson J, Scheynius A (1994).** The prevalence of antinuclear antibodies in substrate. Clin Exp Rheumatol.;12:137–41.
- Fortin E,(1998)** Neurovisual complications of interferon-alpha therapy. Hepatology.;27(5):1441-2.
- Friedman LS(2004)** Controversies in liver biopsy: who, where, when, how and why?. Curr Gastroenterol Rep;6(1):30-36.
- Gatselis N K, Georgiadou S P, Koukoulis G K, Tassopoulos N, Zachou K, Liaskos C, Hatzakis A, Dalekos G N(2006).** Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 24, 1563–1573.
- Gebo KA, Herlong HF, Tobenson MS and et al.(2002)** Role of liver biopsy in management of chronic hepatitis C: A systematic review. Hepatology;36:S161-S172.
- Giovanni S, Marcello P, Marco Lenzi ,Enrico PL, Gaia C,Tea R, Enrico DC, Teresa P,Giovanni R(2003)** High Prevalence of Non-Organ-Specific Auto antibodies in Hepatitis C Virus-Infected Cirrhotic Patients from Southern Italy. Digestive Diseases and Sciences, Vol. 48, No. 2, pp. 349–353.

Reference

Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB(2008) Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. *Am J Kidney Dis.*; 51(2):263-77.

Gordon EW, August(1998) Utilization of short-stay hospital: summary of non medical statistics: United States,64pp., National center for health statistics(NCHS) Vital and health statistics series 13, No.14.

Gregorio GV, Choudhuri K, Ma Y, et al(2003) . Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. *Clin. Exp. Immunol.*;133(3):404-13.

Haddad J, Deny P, Munz-Gotheil C, et al (1992). Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease. *Lancet* 1992; 339: 321-323.

Hadziyannis SJ, et al (2004). Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann. Intern. Med.*;140:346-55.

Reference

Hashimoto E, Ludwig J, MacCarty RL, et al.(1989)

Hepatoportal arteriovenous fistula: morphologic features studied after orthotropic liver transplantation. Hum. Pathol.; 20:707.

Hayashi J, Yoshimura E, Nabeshima A, Kishihara Y, Ikematsu H,

Hirata M, Maeda Y, Kashiwagi S.(1994) Seroepidemiology of hepatitis C virus infection in hemodialysis patients and the general population in Fukuoka and Okinawa, Japan. J Gastroenterol 1994;29:276–281.

Hermann EW, Christian S, Andreas G, Christoph G D, Carsten G, Johann L, Siegfried M, Frank L (2004).

The presence of non-organ-specific auto antibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infectious Diseases 2004, 4:4.

Hochberg MC (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum.;40:1725.

Reference

- Hsieh MY, Dai CY , Lee LP, Huang JF, et al. (2008).** Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C. *J.Clin. Pathol.* 61;333-337.
- Hu KQ, Tong MJ.(1999)** The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. *Hepatology.*; 29(4):1311-6.
- Ishak, Baptista, Bianchi L., et al (1995).** Histological grading and staging of chronic hepatitis. *J. Hepatol.*;22:696-699.
- Jaskowski TD, Schroder C, Martins TB, et al (1996).** Screening for antinuclear antibodies by enzyme immunoassay. *Am J Clin Pathol.*;105:468–473.
- Kawasaki T, Takeshita A, Souda K, Kobayashi Y, Kikuyama M, Suzuki F, Kageyama F, Sasada Y, Shimizu E, Murohisa G, Koide S, Yoshimi T, Nakamura H, Ohno R.(1999)** Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. *Am J Gastroenterol.*; (7): 1918-22.

Reference

Kimberly LB.(2005) Percutaneous liver biopsy coated from handbook of published by LIPPINCOTT WILLIAMS&WILKINS.

Klatskin G, Conn HO.(1993) Histopathology of the liver. New York: Oxford University Press.

Knauer MC.(1978) Percutaneous biopsy of the liver as a procedure for out patients. Gastroenterology; 74:101-102.

Kryczka W, Brojer E, Kowalska A, Zarebska-Michaluk D.(2001) Thyoid gland dysfunctions during antiviral therapy of chronic hepatitis C. Med Sci Monit.:(7)Suppl 1:221-5.

Kulthanan K, Jiamton S, Omcharoen V, Linpiyawan R, Ruangpeerakul J, Sivayathorn A (2002). Autoimmune and rheumatic manifestations and antinuclear antibody study in HIV-infected Thai patients. Int J Dermatol ; 41: 417– 422.

Lau JY, Davis GL, Brunson ME, Qian KP, Lin HJ,Quan S, Dinello R, Polito AJ, Scornik JC.(1993) Hepatitis C virus infection in kidney transplant recipients. Hepatology.;18(5): 1027-31.

Reference

- Lazar H.(1978)** Fractioned liver biopsy needles. Gastroenterology; 74:801.
- Lebrec D.(1996)** Various approaches for obtaining liver tissue: choosing the biopsy technique. J. Hepatol.;25(suppl.1):20.
- Le Frock JL, Ellis CA, Turchick JB, et al.(1975)** Transient bacteraemia associated with percutaneous liver biopsy. J Infect Dis; 131: S 104-107.
- Lenzi M, Bellentani S, Saccoccio G, Muratori P, Masutti F, Muratori L, Cassani F, Bianchi FB, C Tiribelli C (1999).** Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut .;45:435–441.
- Lodish H, Baltimore D, Berk A, et al(1995).** Molecular cell biology. Scientific American books, 3rd ed, Oxford press, New York 1995.p.916.
- Lopes EP, Silva AE, Sette Junior H, Guimaraes RX, Ferraz ML (1995).** Autoantibodies before, during and after administration of recombinant interferon-alpha for chronic viral hepatitis. Rev. Inst. Med. Trop. Sao. Paulo. Sep-Oct;37(5):455-60.

Reference

Maddrey WC.(1999) Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-native patients. *Semin Liver Dis.*;(19) Suppl 1:67-75.

Maillefert JF, Muller G, Falgarone G, et al (2002). Prevalence of hepatitis C virus infection in patients with rheumatoid arthritis. *Ann. Rheum. Dis.*; 61: 635-637.

Manns MP,Mchutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK(2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. *Lancet.*;358(9286)958-65.

Manns MP, Obermayer-Straub P (1997). Viral induction of autoimmunity: mechanisms and examples in hepatology. *J. Viral Hepat.*; 4 (Suppl 2): 42-47.

Manns MP, Rambusch EG (1999). Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. *J. Hepatol*; 31(Suppl 1): 39–42.

Reference

Merican I, Sherlock S, McIntyre N, Dusheiko GM.(1993)

Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection. Q J Med.;86(2): 119-25.

Muratori P, Muratori L, Guidi M, Granito A, Susca M,

Lenzi M, Bianchi FB (2005) Clinical Impact of Non–Organ-Specific Autoantibodies on the Response to Combined Antiviral Treatment in Patients with Hepatitis C. Clin. Infect. Dis.;40:501-507.

Muratori P, Muratori L, Stroffolini T, Pappas G, Terlizzi

P, Ferrari R, Loffreda S, Cassani F, Rapicetta M, Guadagnino V, Bianchi FB, Lenzi M (2003). Prevalence of non-organ specific autoantibodies in HCV infected subjects in the general population. Clin. Exp. Immunol.; 131:118-121.

Pagliari L, Rinaldi F, Craxi A, et al.(1983) Percutaneous

blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial. Dig. Dis. Sci.;28:39-43.

Reference

Patch D.(2005): Liver biopsy chapter 134 coared from clinical gastroenterology and hepatology 1st edition. Page 987 to 991 chapter 134.

Pawlotsky JM (2002). Molecular diagnosis of viral hepatitis. Gastroenterology; 122:1554-68.

Pawlotsky JM, Bouvier M, Fromont P, Deforges L, Duval J, Dhumeaux D, Bierling P.(1995) Hepatitis C virus infection and autoimmune thrombocytopenic purpura. J Hepatol.;23(6): 635-9.

Pereira BJ, Levey AS(1997). Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int.;51(4):981-99.

Piazzolla G, Tortorella C, Fiore G, Fanelli M, Pisconti A, Antonaci S (2001). Interleukin-12 p40/p70 ratio and in vivo responsiveness to IFN-alpha treatment in chronic hepatitis C. J. Interferon Cytokine Res; 21:453-461.

Piccinino F, Sagnelli E, Easquale G, et al.(1986) Complications following percutaneous liver biopsy: a multi center retrospective study on 68, 276 biopsies. J. Hepatology; 2:165.

Reference

Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, Santos J, Coll S, Morillas RM, Sola R.(2004) Natural history of decompensated hepatitis C virus-relate cirrhosis. A study of 200 patients. J Hepatol.;40(5)823-30.

Poniachik J, Bernstein DE, Reddy KR, et al.(1996). The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest. Endosc.;43: 568-571.

Poynard T, Imbert-Bismut F, Ratziu V, et al.(2002) Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: Longtudinal validation in a randomized trial. J. Viral Hepat.,9:128-133.

Poynard T,Munteanu M, Imbert-Bismut F, et al.(2004) Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin. Chem. 50(8): 1344-55.

Prummel MF, Laurberg P (2003). Interferon-alpha and autoimmune thyroid disease. Thyroid; 13: 547-551.

Reference

- Ramos-Casals M, De Vita S, Tzioufas AG(2005).** Hepatitis C virus, Sjogren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer. *Autoimmun Rev.*;4(1):8-15.
- Ramos-Casals M, Loustaud-ratti V, De Vita S, Zeher M, Bosch JA, Toussirot E, Medina F, Rosas J, Anaya JM, Font J, SS-HCV Study Group(2005)** Sjogren syndrome associated with hepatitis C virus: a multi center analysis of 137 cases. *Medicine(Baltimore).*;84(2):81-9.
- Regev A, Berho M, Jeffers LJ, et al.(2002)** Sampling error and intra observer variation in liver biopsy in patients with chronic HCV infection. *Am. J. Gasroenterol.*;97:2614-8.
- Reichert CM, Wiesenthal LM, Klein HG.(1983)** Delayed hemorrhage after percutaneous liver biopsy. *J. Clin. Gastroenterol*; 5:263-266.
- Sansonno D, Cornacchiuolo V, Iacobelli AR, Di Stefano R, Lospalluti M, Dammacco F(1995).** Localization of hepatitis C virus antigens in liver and skin tissues of chronic hepatitis C virusinfected patients with mixed cryoglobulinemia. *Hepatology* ; 21: 305 - 312.

Reference

Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A.(1997) Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. *J Hepatol.*;26(5):961-6.

Sene D, Limal N, Ghillani-Dalbin P, Saadoun D, Piette JC, Cacoub P(2007). Hepatitis C virus-associated B-cell proliferation. the role of serum B lymphocyte stimulator (BLyS/BAFF). *Rheumatology (Oxford).*;46(1):65-9.

Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, Krawczynski K, Conjeevaram HS, Sallie R, Di Bisceglie AM.(1995) Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic and histologic features. The Hepatitis C study Group. *Ann Intern Med.*;123(5):330-7.

Sherlock S, Dooley J.(2002) Anatomy and function; Biopsy of the liver and hepatic cirrhosis. In *Diseases of the liver and Biliary system "11th edition"* , Blackwell Sc. Publ., Oxford, London, Edinburgh,(1):37-44 and (21): 365-377.

Reference

Sherlock S, Dick R, Van Leeuwen DJ.(1984) Liver biopsy today. The Royal Free Hospital experience. J. Hepatol.; 1:75.

Sherlock S, Dooley J.(1997) Diseases of the liver and biliary system, 10th ed. London: Blackwell Scientific; chapter(3): page 33-42.

Simmonds P, et al (2005). Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology;42:962-73.

Spencer-Green G (1998). Outcomes in primary Raynauds phenomenon. Arch Intern Med.;158:595–600.

Stephane C, Jean-Michel P(2006). Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. International Journal of Medical Sciences;3(2):35-40.

Takashi H, Mikio N (2008). Auto antibodies in hepatitis C virus-related chronic liver disease. Hepatitis Monthly, Autumn; 8(4): 295-303

Tan EM, Feltkamp TEW, Smolen JS, et al (1997). Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum.;40:1601–1611.

Reference

- Thornhill MH(2001).** Immune mechanisms in oral lichen planus. *Acta. Odontol Scand*; 59: 174-177.
- Tommy Y, Emmet B, Keefe, Aijaz A,(2003).** The Epidemiology of Hepatitis C Virus Infection. *J. Clin. Gastroenterol.*;36(1):47–53.
- Toubi E, Gordon S, Kessel A, et al (2006).** Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. *J. Autoimmun.*;27(2):134-9.
- Vergani D, Alvarez F, Bianchi FB, Cancado ELR Mackay IR, et al (2004).** Liver autoimmune serology; a consensus statement from the committee for autoimmune serology of the international autoimmune hepatitis group. *J Hepatol* 41:677-83.
- Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. (1997)** Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. *J Clin Microbiol* 1997;35:3274–3277
- Villeneuve JP, Bilodeau M, Lepage R, et al.(1996)** Variability in hepatic iron concentration measurement from needle biopsy specimens. *J. Hepatol.*;25:172.

Reference

- Von Muhlen CA, Tan EM (1995).** Autoantibodies in the diagnosis of systemic rheumatic diseases. *Semin Arthritis Rheum.*;24:23–58.
- Westin J, Lagging LM, Wejstal R, et al.(1999)** Inter-observer study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. *Liver*; 19: 183-187.
- Whitacre CC (2001).** Sex differences in autoimmune disease. *Nat. Immunol*; 2: 777–780.
- Whitmire LF, Galambos JT, Philips VM, et al.(1985)** Imaging guided percutaneous hepatic biopsy: diagnostic accuracy and safety. *J. Clin. Gastroenterol.*; 7:511.
- Whittingham S, McNeilage LJ,(1988).** Antinuclear antibodies as molecular and diagnostic probes. *Mol Cell Probes* 2:169-79.
- WHO. Global surveillance and control of hepatitis C.(1999)** Report of a WHO Consultation organized in collaboration with the Viral. Hepatitis Prevention Board, Antwerp, Belgium. *J Viral Hepat* 1999;6:35–47.
- Wong VS, Egner W, Elsey T, Brown D, Alexander GJ(1996).** Incidence, character and clinical relevance

Reference

of mixed cryoglobulinemia in patients with chronic hepatitis C virus infection. Clin. Exp. Immunol.; 104: 25-31.

Yee L.J, Kelleher P, Goldin R.D, et al. (2004). Antinuclear antibody (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. Journal of Viral Hepatitis. 11, 459-464.

Yen-Chun P, Song-Chou H, Dar- Yu Y, Chun-Fang T, et al(2001). Expression and Clinical Significance of Antinuclear Antibody in Hepatitis C Virus Infection. J Clin Gastroenterol 33(5):402-406.

Zakaria N, Knisely A, Portmann B, et al.(2003) Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy. Blood; 28: 467-474.

Zakim D, Boyer TD.(1996) Fibrosis: representative molecular elements, a basic concept and emerging targets for suppressive treatment (15): 465-498, Hepatic fibrosis and cirrhosis (16): 506-520 and Evaluation of liver function (28): 782-825. In: Hepatology. A text-book of Liver Disease, 3rd ed., Library of Congress, USA.

Zuckerman E, Keren D, Slobodin G, et al(2000). Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon- alpha. J. Rheumatol;27:2172-2178.